High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

Gershon Y. Locker*, Lary Kilton, Janardan D. Khandekar, Thomas E. Lad, Richard H. Knop, Kathy Albain, Richard Blough, Suzanne French, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

Original languageEnglish (US)
Pages (from-to)299-301
Number of pages3
JournalInvestigational New Drugs
Volume12
Issue number4
DOIs
StatePublished - Dec 1 1994

Fingerprint

2-amino-1,3,4-thiadiazole
Non-Steroidal Anti-Inflammatory Agents
Colorectal Neoplasms
Neoplasms
Allopurinol
Chest Pain
Dyspnea
Colonic Neoplasms
Skin
Survival

Keywords

  • ATDA
  • aminothiadiazole
  • colorectal cancer
  • large bowel carcinoma
  • phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Locker, Gershon Y. ; Kilton, Lary ; Khandekar, Janardan D. ; Lad, Thomas E. ; Knop, Richard H. ; Albain, Kathy ; Blough, Richard ; French, Suzanne ; Benson, Al B. / High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial. In: Investigational New Drugs. 1994 ; Vol. 12, No. 4. pp. 299-301.
@article{b6fa42de306c4f6fbe69fdb190c3aae8,
title = "High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial",
abstract = "Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.",
keywords = "ATDA, aminothiadiazole, colorectal cancer, large bowel carcinoma, phase II trial",
author = "Locker, {Gershon Y.} and Lary Kilton and Khandekar, {Janardan D.} and Lad, {Thomas E.} and Knop, {Richard H.} and Kathy Albain and Richard Blough and Suzanne French and Benson, {Al B.}",
year = "1994",
month = "12",
day = "1",
doi = "10.1007/BF00873044",
language = "English (US)",
volume = "12",
pages = "299--301",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

Locker, GY, Kilton, L, Khandekar, JD, Lad, TE, Knop, RH, Albain, K, Blough, R, French, S & Benson, AB 1994, 'High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial', Investigational New Drugs, vol. 12, no. 4, pp. 299-301. https://doi.org/10.1007/BF00873044

High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial. / Locker, Gershon Y.; Kilton, Lary; Khandekar, Janardan D.; Lad, Thomas E.; Knop, Richard H.; Albain, Kathy; Blough, Richard; French, Suzanne; Benson, Al B.

In: Investigational New Drugs, Vol. 12, No. 4, 01.12.1994, p. 299-301.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

AU - Locker, Gershon Y.

AU - Kilton, Lary

AU - Khandekar, Janardan D.

AU - Lad, Thomas E.

AU - Knop, Richard H.

AU - Albain, Kathy

AU - Blough, Richard

AU - French, Suzanne

AU - Benson, Al B.

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

AB - Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

KW - ATDA

KW - aminothiadiazole

KW - colorectal cancer

KW - large bowel carcinoma

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0028641647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028641647&partnerID=8YFLogxK

U2 - 10.1007/BF00873044

DO - 10.1007/BF00873044

M3 - Article

C2 - 7775130

AN - SCOPUS:0028641647

VL - 12

SP - 299

EP - 301

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -